Cargando…
295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not express...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129717/ http://dx.doi.org/10.1017/cts.2023.350 |
_version_ | 1785030811645378560 |
---|---|
author | Santiago-Gonzalez, Juan C. Miranda, Eric Hernandez, Pedro Serrano, Horacio Hallman, Deana |
author_facet | Santiago-Gonzalez, Juan C. Miranda, Eric Hernandez, Pedro Serrano, Horacio Hallman, Deana |
author_sort | Santiago-Gonzalez, Juan C. |
collection | PubMed |
description | OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not expressed in normal control samples obtained from potential organ donors. METHODS/STUDY POPULATION: A pilot study with ten patients undergoing surgery for pancreatic cancer will obtain tumor tissue and blood samples. Protein extracts isolated from tissue/cells will be reduced, alkylated, and digested overnight. Samples will be labeled with TMT reagents and mixed before fractionation and cleanup. Labeled samples will be analyzed with a high-resolution Orbitrap LC-MS/MS before data analysis to identify peptides and quantify the reporter ions. The altered proteins will be analyzed by ELISA to confirm their presence. The protein arrangements will be compared with results from proteomic profile banks to assess their prevalence. As controls, parallel protein analyses will be performed on normal tissue/blood samples from organ donors, facilitated by our local organ procurement organization. RESULTS/ANTICIPATED RESULTS: We anticipate finding proteogenomic material defining PC and new proteomic subtypes not previously described in this population. In addition, studying protein overexpression and underexpression can identify relevant genes and potential biomarkers. We hypothesize that PC in the Hispanic population will show slight variations in tumor protein expression than in other populations, which could lead to the discovery of a new Hispanic-specific biomarker. DISCUSSION/SIGNIFICANCE: We expect to provide essential information that will influence the next steps in developing future screening tests. Identifying specific proteins with the potential to become a preventive test should eventually lead to a reduction in morbidity and mortality of PC. The results of this work should lay the foundation that can guide future research. |
format | Online Article Text |
id | pubmed-10129717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101297172023-04-26 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer Santiago-Gonzalez, Juan C. Miranda, Eric Hernandez, Pedro Serrano, Horacio Hallman, Deana J Clin Transl Sci Precision Medicine/Health OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not expressed in normal control samples obtained from potential organ donors. METHODS/STUDY POPULATION: A pilot study with ten patients undergoing surgery for pancreatic cancer will obtain tumor tissue and blood samples. Protein extracts isolated from tissue/cells will be reduced, alkylated, and digested overnight. Samples will be labeled with TMT reagents and mixed before fractionation and cleanup. Labeled samples will be analyzed with a high-resolution Orbitrap LC-MS/MS before data analysis to identify peptides and quantify the reporter ions. The altered proteins will be analyzed by ELISA to confirm their presence. The protein arrangements will be compared with results from proteomic profile banks to assess their prevalence. As controls, parallel protein analyses will be performed on normal tissue/blood samples from organ donors, facilitated by our local organ procurement organization. RESULTS/ANTICIPATED RESULTS: We anticipate finding proteogenomic material defining PC and new proteomic subtypes not previously described in this population. In addition, studying protein overexpression and underexpression can identify relevant genes and potential biomarkers. We hypothesize that PC in the Hispanic population will show slight variations in tumor protein expression than in other populations, which could lead to the discovery of a new Hispanic-specific biomarker. DISCUSSION/SIGNIFICANCE: We expect to provide essential information that will influence the next steps in developing future screening tests. Identifying specific proteins with the potential to become a preventive test should eventually lead to a reduction in morbidity and mortality of PC. The results of this work should lay the foundation that can guide future research. Cambridge University Press 2023-04-24 /pmc/articles/PMC10129717/ http://dx.doi.org/10.1017/cts.2023.350 Text en © The Association for Clinical and Translational Science 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. |
spellingShingle | Precision Medicine/Health Santiago-Gonzalez, Juan C. Miranda, Eric Hernandez, Pedro Serrano, Horacio Hallman, Deana 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title | 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title_full | 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title_fullStr | 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title_full_unstemmed | 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title_short | 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer |
title_sort | 295 identification of proteomic biomarkers in puerto ricans with pancreatic cancer |
topic | Precision Medicine/Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129717/ http://dx.doi.org/10.1017/cts.2023.350 |
work_keys_str_mv | AT santiagogonzalezjuanc 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer AT mirandaeric 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer AT hernandezpedro 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer AT serranohoracio 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer AT hallmandeana 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer |